Form4insider filings, from the source

SEC Form 3 · accession 0001193125-26-333373

Attovia Therapeutics, Inc. · ATTO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Attovia Therapeutics, Inc.
Officer — President and CEO · Director
Period of report
Aug 4, 2026
Accepted (ET)
Aug 4, 2026 · 7:31 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0002058707

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common Stockholding———87,843D
Common StockF1holding———99,181IBy Trust
Common StockF2holding———116,103IBy Trust
Common StockF3holding———245,425IBy Trust

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock Option (Right to Buy)F4$1.5793holding————Aug 16, 2033Common Stock23,437—D
Stock Option (Right to Buy)F5$3.5302holding————May 8, 2034Common Stock409,709—D
Stock Option (Right to Buy)F6$4.9237holding————May 17, 2035Common Stock370,290—D

Explanation of responses

Remarks

EX - 24.1 Power of Attorney